Numab Therapeutics AG: Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program : vimarsana.com

NM26-2198 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets for the treatment of moderate to severe atopic dermatitis (AD) Combined single ascending dose

Related Keywords

United States , Zurich , Züsz , Switzerland , Kaken , Niedersachsen , Germany , Japan , Japanese , America , David Urech , Sara Michelmore , Peter Lichtlen , European Union , Chief Executive Officer , Chief Medical Officer , Kaken Pharmaceutical , While Kaken , Executive Officer , Dougall Advisors , Gefallene Big Techs , Numab , Herapeutics , Nnounces , Irst , Ubject , Osed , Hase , Linical , Tudy , M26 , Rogram ,